Capricor Therapeutics Inc [CAPR] stock prices are up 11.65% to $15.05 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CAPR shares have gain 5.02% over the last week, with a monthly amount glided 18.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on October 21, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $35. Previously, Oppenheimer started tracking the stock with Outperform rating on May 17, 2024, and set its price target to $14. On January 05, 2024, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $8 on the stock. Ladenburg Thalmann started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 26, 2022. Maxim Group downgraded its rating to a Hold. H.C. Wainwright reiterated a Buy rating for this stock on January 26, 2018, and upped its price target to $8.60. In a note dated September 15, 2017, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $2.15 to $6.50.
The stock price of Capricor Therapeutics Inc [CAPR] has been fluctuating between $3.52 and $23.40 over the past year. Currently, Wall Street analysts expect the stock to reach $15.38 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $15.05 at the most recent close of the market. An investor can expect a potential return of 2.19% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
The Capricor Therapeutics Inc [NASDAQ:CAPR] reported sales of 23.23M for trailing twelve months, representing a drop of -63.44%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.55%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -1.13 and Total Capital is 0.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.68 points at the first support level, and at 12.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.94, and for the 2nd resistance point, it is at 16.83.
Ratios To Look Out For
It’s worth pointing out that Capricor Therapeutics Inc [NASDAQ:CAPR]’s Current Ratio is 4.19. In addition, the Quick Ratio stands at 4.19 and the Cash Ratio stands at 0.0. Considering the valuation of this stock, the price to sales ratio is 29.46, the price to book ratio is 8.89.
Transactions by insiders
Recent insider trading involved Nippon Shinyaku Co Ltd, 10% Owner, that happened on Sep 20 ’24 when 2.8 million shares were purchased.
